Cette journée a obtenu un agrément FMC
LE PSORIASIS DANS TOUS SES ETATS
a eu lieu le vendredi 7 octobre 11, à l’Institut Pasteur, Paris.
Programme :
9h00 : Accueil des participants
9h30-9h35 : Introduction - H. Bachelez (Paris)
9h35-10h00 : Traitements du psoriasis de l’enfant - S. Barbarot (Nantes)
10h00-10h25 : Traitement du psoriasis du cuir chevelu : quel algorythme thérapeutique ? - P. Reygagne (Paris)
10h25-10h50 : Actualités sur la prise en charge du psoriasis unguéal - R. Baran (Cannes)
10h50-11h00 : Pause
11h00-11h30 : Quels traitements antipsoriasiques prescrire au cours de la grossesse ? - E. Elefant (Paris)
11h30-11h55 : Quelle prise en charge en pratique pour les éruptions paradoxales induites par les inhibiteurs du TNF ? - F. Aubin (Besançon)
11h55-12h20 : Les psoriasis pustuleux sont-ils des syndromes auto-inflammatoires ? - H. Bachelez (paris)
12h20-12h45 : Actualités thérapeutiques - C. Paul (Toulouse)
12h45-14h00 : Déjeuner
14h00-14h30 : Rôle des agents infectieux dans les maladies inflammatoires - Conférence CRI-Groupe de recherche sur le Psoriasis - J. Sibilia (Strasbourg)
14h30-16h30 : Cas cliniques interactifs - M. Le Maître (Caen), M. Beylot Barry (Bordeaux), V. Descamps (Paris)
Secrétariat d’organisation : Kobé - Groupe GL events
L’accès aux diaporamas des différentes conférences est restreint, inscrivez-vous pour y avoir accès.
SPIN Presentation
Recent news
- 2019/10/29 Focus on...
- 2019/08/12 Focus on...
Latin American Clinical Practice Guidelines on the Systemic Treatment of Psoriasis
- 2019/06/03 Focus on...
- 2019/05/21 Focus on...
- 2019/04/18 Focus on...
News from the web office
- 2016/10/29
- 2016/05/26
- 2016/02/20
Events
- 2019/04/18 Focus on...
- 2018/02/21
News from medical groups
- 2018/04/18
- 2017/06/21
News from patients associations
- 2017/02/08
- 2016/05/26
Recent publications on Psoriasis and Atopic Dermatitis
on Psoriasis
Our ambition in a changing landscape of psoriasis treatments.
van de Kerkhof PCM et al.
Our ambition in a changing landscape of psoriasis treatments.
J Dermatolog Treat.
2020 Mar , 31, (2):105-107.
CARD14/CARMA2sh and TANK differentially regulate poly(I:C)-induced inflammatory reaction in keratinocytes.
J. Cell. Physiol..
2020 Mar , 235, (3):1895-1902.
CARD14/CARMA2sh (CARMA2sh) is a scaffold protein whose mutations are associated with the onset of human genetic psoriasis and other inflammatory skin disorders. Here we show that the immunomodulatory adapter protein TRAF family member-associated NF-κB activator (TANK) forms a complex with CARMA2sh and MALT1 in a human keratinocytic cell line. We also show that CARMA2 and TANK are individually required to activate the nuclear factor κB (NF-κB) response following exposure to (...)
see on pubmed
Prohibitin 1 interacts with signal transducer and activator of transcription 3 in T-helper 17 cells.
Immunol. Lett..
2020 Mar , 219:8-14.
T-helper 17 (Th17) cells are involved in the occurrence and development of several inflammation-associated diseases. Interleukin (IL)-17, the main cytokine secreted by differentiated Th17 cells, mediates immunoreactions and plays important roles in immunological diseases, including psoriasis, rheumatic arthritis, and inflammatory bowel disease. The maturation and stabilization of the differentiated Th17 cell phenotype are associated with the expression of IL-17A, which is induced by the (...)
see on pubmed
on Atopic Dermatitis
Off-label studies on apremilast in dermatology: a review.
Maloney NJ et al.
Off-label studies on apremilast in dermatology: a review.
J Dermatolog Treat.
2020 Mar , 31, (2):131-140.
Apremilast is a phosphodiesterase-4 inhibitor FDA approved for psoriatic arthritis and moderate to severe plaque psoriasis. In recent years, multiple studies have suggested other potential uses for apremilast in dermatology. A summary of these various studies will be a valuable aid to dermatologists considering apremilast for an alternative indication. The PubMed/MEDLINE and ClinicalTrials.gov databases were queried with the term 'apremilast,' with results manually screened to identify (...)
see on pubmed
Atopic dermatitis induces anxiety- and depressive-like behaviors with concomitant neuronal adaptations in brain reward circuits in mice.
Prog. Neuropsychopharmacol. Biol. Psychiatry.
2020 Mar 02, 98:109818.
Clinically, it has been reported that atopic dermatitis (AD) has been linked with negative emotional problems such as depression and anxiety, thereby reducing the quality of life, but little is known about the molecular mechanism that underlies AD-associated emotional impairments. We sought to determine whether AD could induce anxiety- and depressive-like symptoms in mice and to identify pertinent signaling changes in brain reward circuitry. AD-like lesions were induced by the repeated (...)
see on pubmed
Efficacy and safety of indigo naturalis ointment in Treating Atopic Dermatitis: A randomized clinical trial.
J Ethnopharmacol.
2020 Mar 25, 250:112477.
Indigo naturalis, a herbal medicine with a history of use dating back to ancient times, may be a good alternative topical treatment for atopic dermatitis (AD).
see on pubmed
